FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
1	Estimated average b	urden								

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,				' '								
1. Name and Address of Reporting Person* <u>Horton Kenneth L</u>				VI	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									Check all a	hip of Reportir pplicable) ector	ng Perso	on(s) to Is		
(Last)	(Fir	est) (Middle)		- 11/1	<u>△</u> [VKIA	J								icer (give title ow)		Other (below)	(specify
C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 10/30/2014									-	r				
50 NORTHERN AVENUE				4. If	If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														["	,	rm filed by On	e Repor	rting Pers	on
BOSTON MA 02210															Form filed by More than One Reporting Person				
(City)	(Sta	ate) (Zip)																
		Tabl	e I - No	n-Deri\	/ative	Sec	curitie	s Ac	quired	, Dis	posed o	f, or	Bene	ficia	ally Ow	ned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		Code	Transaction Disposed Code (Instr. 5)					nd Sec Ben Owi	mount of urities eficially led Following orted	Form: (D) or	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		A) or D)	Price	Trai	saction(s) r. 3 and 4)			(111511.4)
Common Stock 10/3				10/30)/2014	2014		A		40,000	(1)	Α	\$ <mark>0</mark> .	01	72,463		D		
Common Stock														366		I	401(k)		
		Та									sed of, onvertib				y Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	Code (Ins				6. Date Exercis Expiration Date (Month/Day/Ye		е	7. Title and Amount of Securities Underlying Derivative Security (Instr and 4)			8. Price of Derivative Security (Instr. 5)		Ow For Dir or (I)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Num of Sha	ber					

Explanation of Responses:

Remarks:

Kenneth L. Horton

11/03/2014

tlv.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on October 30, 2017 (or, if later, the day following the earnings release for the third quarter of 2017) if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 1, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release.